Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. The six-month engagement, valued at US$250,000, includes company profile creation, media distribution, digital community development, news marketing, and lead generation campaigns. According to the company, IR Agency LLC is arm’s-length and holds no direct or indirect equity interest in Quantum’s securities.
This move signals Quantum’s intent to amplify its corporate narrative amid a competitive biotech landscape. For leaders in business and technology, the partnership underscores the growing importance of targeted investor communications in attracting capital for advanced therapies. Quantum focuses on neurodegenerative and metabolic disorders, alcohol misuse, and multiple sclerosis (MS) through its subsidiary Lucid Psycheceuticals Inc. Its lead compound, Lucid-MS, is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS.
Quantum also holds a 19.84% stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), the company behind UNBUZZD(TM), an over-the-counter product. The agreement includes royalty payments: 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses. This structure provides a potential recurring revenue stream while Quantum advances its pipeline.
The investor relations engagement comes as Quantum seeks to differentiate itself in a sector where funding is often tied to clinical milestones. The company’s newsroom at https://ibn.fm/QNTM will feature updates. For investors, clear communication of scientific progress and market opportunities is critical. The partnership with Stocks.news, detailed in the full press release at https://ibn.fm/iBZrw, aims to ensure Quantum’s story reaches a broader audience.
Industry observers note that effective investor relations can influence stock liquidity and analyst coverage, especially for small-cap biotechs. As Quantum advances Lucid-MS and other candidates, the ability to articulate value to stakeholders becomes paramount. The $250,000 fee reflects a significant investment in visibility, which may impact the company’s near-term cash position but could pay dividends through increased investor interest.
For business and technology leaders, the announcement highlights the strategic role of communications in biotech. As the sector evolves, companies that master the narrative around their science and commercial potential may gain a competitive edge. Quantum’s focus on MS and metabolic disorders addresses large markets, and its royalty arrangement with Unbuzzd adds a non-dilutive revenue component. The investor relations agreement is a tactical step toward ensuring these elements are effectively conveyed.
